Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction

Author:

Adamson Philip B.1,Abraham William T.1,Bourge Robert C.1,Costanzo Maria Rosa1,Hasan Ayesha1,Yadav Chethan1,Henderson John1,Cowart Pam1,Stevenson Lynne Warner1

Affiliation:

1. From the Heart Failure Institute, Oklahoma Heart Hospital, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City (P.B.A.); Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University, Columbus (W.T.A., A.H.); Department of Medicine, University of Alabama at Birmingham (R.C.B.); Advocate Medical Group-Midwest Heart Specialists Heart Failure and Pulmonary Arterial Hypertension Programs, Edward Hospital Center for Advanced Heart...

Abstract

Background— No treatment strategies have been demonstrated to be beneficial for the population for patients with heart failure (HF) and preserved ejection fraction (EF). Methods and Results— The CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial was a prospective, single-blinded, randomized controlled clinical trial testing the hypothesis that hemodynamically guided HF management decreases decompensation leading to hospitalization. Of the 550 patients enrolled in the study, 119 had left ventricular EF ≥40% (average, 50.6%), 430 patients had low left ventricular EF (<40%; average, 23.3%), and 1 patient had no documented left ventricular EF. A microelectromechanical system pressure sensor was permanently implanted in all participants during right heart catheterization. After implant, subjects were randomly assigned in single-blind fashion to a treatment group in whom daily uploaded pressures were used in a treatment strategy for HF management or to a control group in whom standard HF management included weight-monitoring, and pressures were uploaded but not available for investigator use. The primary efficacy end point of HF hospitalization rate >6 months for preserved EF patients was 46% lower in the treatment group compared with control (incidence rate ratio, 0.54; 95% confidence interval, 0.38–0.70; P <0.0001). After an average of 17.6 months of blinded follow-up, the hospitalization rate was 50% lower (incidence rate ratio, 0.50; 95% confidence interval, 0.35–0.70; P <0.0001). In response to pulmonary artery pressure information, more changes in diuretic and vasodilator therapies were made in the treatment group. Conclusions— Hemodynamically guided management of patients with HF with preserved EF reduced decompensation leading to hospitalization compared with standard HF management strategies. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00531661.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 370 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies;International Journal of Cardiology;2024-10

2. Left Ventricular Diastolic Dysfunction in Cardiac Surgery: A Narrative Review;Journal of Cardiothoracic and Vascular Anesthesia;2024-10

3. Clinical Update in Heart Failure with Preserved Ejection Fraction;Current Heart Failure Reports;2024-09-03

4. Design and Rationale of the V-Wave Shunt MitraClip Study;The American Journal of Cardiology;2024-09

5. Contemporary treatment options in heart failure with preserved ejection fraction;European Heart Journal - Cardiovascular Imaging;2024-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3